Clinical Impact of CDK4/6 Inhibitors in De Novo or PR− or Very Elderly Post-Menopausal ER+/HER2− Advanced Breast Cancers

SIMPLE SUMMARY: The cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors palbociclib, ribociclib and abemaciclib have transformed the lives of patients with ER+/HER2− metastatic breast cancer (MBC). Clinical trials have shown that all three CDK4/6 inhibitors improve progression-free survival (PFS), but...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Hiu, Yeo, Daniel, De Souza, Karen, Ahmad, Omar, Shafiq, Tahir, Ofor, Okezie, Anand, Anjana, Karim, Syed, Khan, Sarah, Madhusudan, Srinivasan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647609/
https://www.ncbi.nlm.nih.gov/pubmed/37958338
http://dx.doi.org/10.3390/cancers15215164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647609/
https://www.ncbi.nlm.nih.gov/pubmed/37958338
http://dx.doi.org/10.3390/cancers15215164

Ejemplares similares